What Is KLOW Blend? The Four-Peptide Repair Formula, Explained in Full

KLOW is not a single molecule. It is four independently studied peptides — GHK-Cu, KPV, BPC-157 and TB-500 — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Each has its own research literature, its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination; it does not appear in any journal. That shapes everything on this page: "does KLOW work" has to be broken into four questions, because the combination itself has never been studied as a combination.

The rationale prescribers give is that tissue repair runs in overlapping phases — inflammation, cell migration, new blood-vessel growth, matrix synthesis, remodelling — and each component is described in the research as acting on a different phase. Combining them covers the whole sequence with one injection rather than four.

The proportions are worth noticing. GHK-Cu is 50 of the 80 mg in the vial, so by mass KLOW is mostly a GHK-Cu preparation with three smaller components. The ratio is fixed by the pharmacy's formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not a painkiller and has no described analgesic mechanism. It is not a treatment for a structural problem — a full-thickness tendon rupture, a displaced fracture or a locking joint is a surgical or imaging question, and no peptide changes that. It is not a hormone, a steroid or a growth-hormone secretagogue. And it is not a shortcut around rehabilitation: every component is described as supporting a repair process the body is already running, not as creating one.

GHK-Cu is a tripeptide — glycine, histidine, lysine — that binds copper with high affinity. It occurs naturally in human plasma, where its concentration is reported to decline with age. The copper-carrying role is the basis for most of its described effects, because collagen cross-linking, elastin formation and several antioxidant enzymes are copper-dependent.

In cell and animal work, and in reviews in Biomed Research International (2015) and the International Journal of Molecular Sciences (2018), GHK-Cu is described as increasing synthesis of collagen, elastin, proteoglycans and glycosaminoglycans, and as shifting the balance between matrix metalloproteinases, which break tissue down, and their inhibitors. Gene-expression work reports effects across a large number of genes rather than one pathway, which is why the literature discusses it as resetting tissue toward a repair pattern. It is also described as supporting angiogenesis and as having antioxidant and anti-inflammatory activity in those models.

KPV is the last three amino acids — lysine, proline, valine — of alpha-melanocyte-stimulating hormone. Alpha-MSH does two separate things: it drives pigmentation through the melanocortin-1 receptor, and it has anti-inflammatory effects. The isolated C-terminal tripeptide is reported to keep the anti-inflammatory activity while losing the pigmentation effect, which is why KPV does not darken skin.

Cell and animal studies describe KPV interfering with intracellular inflammatory signalling, including the NF-kB pathway, and reducing output of pro-inflammatory cytokines such as TNF-alpha and IL-6. A 2008 paper in Gastroenterology reported that the tripeptide is taken up into intestinal cells by the PepT1 transporter and reduced inflammation in mouse colitis models; a 2008 review in Endocrine Reviews covers the wider alpha-MSH and tripeptide literature. In a repair blend, the logic is that inflammation which never resolves is the commonest reason a repair phase stalls.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice. Animal work describes it activating the VEGFR2 receptor and downstream nitric-oxide signalling, which is the axis the body uses to grow new blood vessels into healing tissue. A 2014 paper in Molecules reported that BPC-157 increased growth hormone receptor expression in cultured tendon fibroblasts and activated the FAK–paxillin pathway that governs cell attachment and migration. The receptor finding is often misread: it describes making those cells more responsive to growth hormone already present, not raising growth hormone.

Separately, the largest body of BPC-157 research concerns protection of the gastrointestinal lining in animal models, which is where the compound was first identified. A fuller treatment is on the BPC-157 page.

TB-500 is a synthetic peptide reproducing the actin-binding segment of thymosin beta-4, a 43-amino-acid protein that is one of the most abundant inside many human cells. Thymosin beta-4's primary described function is binding actin monomers, the protein that gives a cell its shape and lets it move.

The consequence described in the research is cell migration: repair cells moving into a wound. A 1999 paper in the Journal of Investigative Dermatology reported faster wound closure and increased cell migration with thymosin beta-4 in rats and in cultured human cells, and a 2012 review in Expert Opinion on Biological Therapy summarises the wider literature, including described effects on angiogenesis, inflammatory mediators and laminin-5. One point of precision: most of that literature concerns the full-length protein. TB-500, the fragment, is assumed to share the actin-binding mechanism; the direct evidence for the fragment itself is much thinner.

The repair-phase map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the four act in sequence when injected together.

GHK-Cu has the deepest literature of the four and is the only component with human studies of any size. The human work is mostly small studies of topical GHK-Cu on facial skin — reporting changes in firmness, fine lines and elasticity — and observational wound-healing reports, summarised in the 2015 and 2018 reviews above. None of the human studies used the injectable form.

This rests on BPC-157 and, by extension from thymosin beta-4, on TB-500. A 2003 paper in the Journal of Orthopaedic Research examined transected Achilles tendon in rats and reported faster reattachment and better functional recovery in treated animals. Animal models of muscle crush injury report faster functional recovery. For TB-500, the tendon and muscle case is inferred from the full-length protein's wound-healing work rather than shown directly.

KPV's evidence is animal and cell work, mainly in models of gut and skin inflammation, of which the 2008 mouse colitis study is the best known; there is no human trial of KPV for any indication. BPC-157's original and largest literature is gastrointestinal: animal work describing protection against NSAID- and alcohol-induced gastric damage and improvement in inflammatory bowel models. It is why a gut complaint is usually a reason to consider BPC-157 on its own rather than KLOW.

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of KLOW, or of any four-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• GHK-Cu has small human studies, mostly of topical application to skin, plus observational wound-healing reports. There are no randomised controlled trials of injectable GHK-Cu.
• KPV has no human trials of any kind. Its evidence is animal and cell work.
• BPC-157 has early-phase human work for inflammatory bowel indications and substantial prescribing experience. There are no large randomised controlled trials in humans, and none for tendon or soft-tissue injury.
• TB-500 has no randomised human trials. The full-length thymosin beta-4 protein has been studied in early-phase human trials for chronic dermal wounds and corneal conditions, reviewed in the 2012 paper above, but those used the whole protein, not the fragment.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe KLOW on. But the accurate framing is "described in preclinical research and used clinically," not "proven in people."

• That four peptides together do more than any one alone. No study has compared the blend with its components.
• An effect size for any indication, because those trials have not been run.
• A timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety over years of continuous use, which is part of why a physician reviews each refill.
• Efficacy for any condition as an FDA-approved treatment. Neither KLOW nor any component is approved for anything.

Between 2023 and early 2026 all four components sat in Category 2 of the FDA's 503A bulk drug substances list — the category for substances the agency had flagged as presenting significant safety risks. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective about a week later, and BPC-157, KPV, TB-500 and injectable GHK-Cu were all among them. The non-injectable form of GHK-Cu, which had sat in Category 1, was removed from that list at the same time.

Removal from Category 2 lifts the safety-risk designation. It does not, by itself, place a substance on the positive 503A Bulks List; that requires an advisory committee review and a final FDA determination.

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted, 8–6 with one abstention in each case, to recommend adding BPC-157, KPV and TB-500 — each as the free base and the acetate — to the 503A Bulks List. FDA's own scientists had recommended against inclusion for each, citing insufficient safety, efficacy and characterisation data; the committee weighed the presentations and voted the other way.

A committee vote is a recommendation, not a decision. The FDA issues its own determination through notice-and-comment rulemaking, and that determination is still pending as of September 2026.

GHK-Cu was not on the July agenda. The FDA has said the committee will consider it, along with several other April removals, at a meeting to be held before the end of February 2027. Until then it is where the other three were between April and July: no longer flagged, not yet reviewed for the positive list.

None of the four components is restricted; three have been formally recommended for the positive list and await final FDA action; the fourth is scheduled for review. None is an FDA-approved drug product, and compounded medications never are — they are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products.

Most people notice little or nothing. Injection-site tenderness is the most commonly reported observation. Some describe background inflammation settling in a problem area, but noticing nothing in this window is normal and is not a sign the course is not working.

This is where prescribers most often describe a reduced background ache in the affected area and, for those tracking skin, a sense of better hydration. It is the window one vial covers on a weekday schedule.

Where tissue-level change happens, this is where it would be expected to show, based on the animal timelines for the tendon and soft-tissue work. Prescribers describe it as improved tolerance to loading — the point at which rehabilitation progress usually becomes visible. It typically takes a second vial to reach.

Skin turnover is slow, and GHK-Cu's described effects on collagen and matrix are slow by nature; prescribers who use KLOW with skin quality as a goal describe texture and tone changes, where they occur, as a two-month-plus proposition. Nothing produces visible skin change in two weeks. After a course there is no withdrawal and no rebound described for any component; whether any benefit persists depends on whether the underlying tissue actually changed.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the four are in fixed proportion, every dose delivers the same split: 2.5 mg GHK-Cu, 0.5 mg KPV, 0.5 mg BPC-157 and 0.5 mg TB-500; you cannot take more of one and less of another. If your directions and syringe markings appear to disagree, ask before dosing. How to inject peptides safely covers technique.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. Some prescribers direct injection near the affected area; others do not, because the mechanisms described are systemic. Your directions will say.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a monthly cycle. Weekends off is part of the schedule, not a missed dose. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating is on the label; a multi-peptide vial is not something to keep past it. How to store peptides covers this properly.

The only difference is KPV. GLOW is the same three repair peptides — GHK-Cu, BPC-157, TB-500 — without the anti-inflammatory tripeptide. If persistent inflammation is part of your picture, KLOW is the fuller formula; if it is not, GLOW covers the repair case with one fewer component.

The two-peptide stack is the injury-only version. It omits GHK-Cu, which is the skin and matrix component and the majority of KLOW by mass, and KPV. For a single tendon or ligament problem it is the more targeted prescription and a physician may reasonably prefer it. A gut complaint narrows further, to BPC-157 alone.

Identical medication. The pepti Pen is a pre-filled 3 mL cartridge in a reusable click-dial injector, the same four peptides at the same totals, dosed in clicks rather than drawn with a syringe. It costs more and removes the draw step. Neither is clinically better.